-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 21, 2021, Novo Nordisk announced that it will launch a pivotal phase 3a clinical trial to test oral smeglutide in approximately 1,000 obese or overweight patients with comorbidities.
1.
1.
2.
2.
3.
3.
4.
4.
Reference materials:
[1] Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide Retrieved April 21, 2021, fromNordisk-to-initiate-phase-3a-development-in-obesity-with-oral-semaglutide.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.